Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial. J of Skin. 2021;5(6):s52. doi:10.25251/skin.5.supp.52